Medidata RTSM vs Prancer RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Medidata RTSM

Best for
Sponsors already on Rave EDC who want randomization and supply in the same system
What to consider
Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.
Read product profile

Prancer RTSM

Best for
Sponsors and CROs with complex dosing or adaptive designs who want an RTSM specialist with supply forecasting
What to consider
4G Clinical is an RTSM specialist: Prancer covers randomization, resupply and direct-to-patient shipping, and 4C Supply adds portfolio-level forecasting. It publishes a SOC 2 Type 2 report and a Part 11 statement, and says it has supported more than 1,000 studies. It has no EDC or eCOA of its own, so plan for integrations.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Medidata RTSM vs Prancer RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureMedidata RTSMPrancer RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Extended support

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source
About this support label

Named methods include permuted blocks and dynamic allocation with stratification.

Extended support

4G names stratification, cohort-specific logic, variable blocks and minimization, with versioned logic that protects blinding and handles re-randomization.

Source
About this support label

Named methods include variable blocks and minimization with blinding protection.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source
About this support label

Predictive supply schemes and forecasting are documented alongside direct-to-patient shipments.

Extended support

Prancer handles dispensing and resupply with buffer-to-predictive forecasting and 4C Supply scenario modeling; direct-to-patient shipping was added in April 2020 (4G blog).

Source
About this support label

Predictive resupply, scenario modeling and direct-to-patient shipping are stated.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source
About this support label

A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.

Supported

4G says its NLP-based build takes under four weeks, with specification sign-off to go-live in as little as 13 calendar days, and changes made without impacting study progress.

Source
About this support label

A build timeline and changes protecting study progress are stated; uninterrupted live use is not explicit.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Supported

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source
About this support label

Rave and depot integrations establish base support; an API is not stated in this note.

Supported

4G documents connections to EDC, CTMS, depot and logistics systems and data warehouses, but has no EDC or eCOA of its own and we found no public API reference.

Source
About this support label

Connections to trial systems establish base support; a public API reference was not found.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source
About this support label

A certificate and audit are listed, but public document access is not established; trial statements require customer login.

Supported

The trust center reports a SOC 2 Type 2 report for the 12 months ending 31 August 2026 and states compliance with 21 CFR Part 11 and EU Annex 11.

Source
About this support label

Trial standards and a dated SOC report period are stated; public report access is not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
About this support label

Product-specific monthly patient usage is reported alongside a stated country count.

Supported

4G says it has evolved to support more than a thousand studies worldwide.

Source
About this support label

Study adoption is reported worldwide, but no country count is given.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.